Cycle Pharmaceuticals appoints Steve McCue as Chief Financial Officer
May 25th 2021
Cycle Pharmaceuticals appoints Steve McCue as Chief Financial Officer
Cambridge, U.K., 25 May 2021 – Cycle Pharmaceuticals Ltd announced earlier this month that Steve McCue is appointed Chief Financial Officer, effective 10th May, 2021.
Steve McCue brings an extensive international experience gained across sectors such as specialty chemicals, electronics manufacturing, and more recently high-volume wholesale distribution.
As CFO, Mr McCue will lead Cycle’s global finance organization and will be responsible for accounting, treasury, financial planning and analysis, tax, investor relations and information technology.
“I am pleased to welcome Steve to our leadership team,” said Antonio Benedetti, Cycle’s CEO. “Steve is a key hire that builds on Cycle’s momentum and positions the company for continued rapid expansion and accelerated growth. His deep and extensive experience in leading the financial operations of industrial global businesses – as well as driving operational changes – will make an immediate impact on our growth plans. Steve will provide strong leadership and is an excellent addition to the Cycle team.”
“I am delighted to join Cycle, a company that is rewriting the way to serve Rare Disease patients”, said Mr McCue. “Cycle has unique strengths, and I look forward to working with the team to execute on the company’s priorities, accelerate growth and enhance value for shareholders and all stakeholders.”
Before joining Cycle, Mr McCue was Group CFO of Antalis SA, the Euronext listed leading distributor of paper, packaging and visual communication materials.
Prior to Antalis, Mr McCue spent 15 years with the large US privately held industrial corporate, JM Huber, across two divisions of the business. Initially, within the high-volume electronics manufacturing business, he held senior financial and general management roles in Europe and Asia. Mr McCue then joined the speciality chemicals business, CP Kelco, a global leader in hydrocolloids, serving regulated markets such as food and pharma, where he held both finance leadership positions as well as managing a global product line as Global Business Director whilst living and working across a number of European countries.
GL-CC-2100003 (May 2021)